Imbruvica and Cholecystitis - a phase IV clinical study of FDA data

Summary:

Cholecystitis is reported as a side effect among people who take Imbruvica (ibrutinib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Tylenol, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Cholecystitis when taking Imbruvica. It is created by eHealthMe based on reports of 69,938 people who have side effects when taking Imbruvica from the FDA, and is updated regularly.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

What is Cholecystitis?

Cholecystitis (infection of gallbladder) is found to be associated with 1,167 drugs and 1,218 conditions by eHealthMe. Check the latest studies of Cholecystitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

69,938 people reported to have side effects when taking Imbruvica.
Among them, 29 people (0.04%) have Cholecystitis.

Among these 29 people:

How long have people been on Imbruvica when they have Cholecystitis? *

What is the gender of people who have Cholecystitis when taking Imbruvica? *

female: 24.14 %
male: 75.86 %

What is the age of people who have Cholecystitis when taking Imbruvica? *

What are other drugs people take besides Imbruvica? *

What are other side effects people have besides Cholecystitis? *

Gallstones (stone formation by bile component): 7 people, 24.14%
Abdominal Pain: 3 people, 10.34%
Thrombocytopenia (decrease of platelets in blood): 3 people, 10.34%
Pancreatitis (inflammation of pancreas): 3 people, 10.34%
Blood Bilirubin Increased: 3 people, 10.34%
Head Injury: 3 people, 10.34%
Fatigue (feeling of tiredness): 3 people, 10.34%
Weight Decreased: 3 people, 10.34%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 6.90%
Temporal Lobe Epilepsy (a term that refers to a condition where seizures are generated in the portion of the brain called the temporal lobe): 2 people, 6.90%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 22 people, 75.86%
Pain: 4 people, 13.79%
Indigestion: 3 people, 10.34%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 10.34%
High Blood Cholesterol: 3 people, 10.34%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 10.34%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 6.90%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 2 people, 6.90%
Chronic Lymphocytic Leukaemia Recurrent (repeated cancer of blood cells known as lymphocytes): 2 people, 6.90%
Thyroid Diseases: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and have Cholecystitis?

- Check whether Cholecystitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imbruvica:

Imbruvica (70,020 reports)

Cholecystitis treatments and more:

Cholecystitis (16,481 reports)

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cholecystitis:

Cholecystitis (1,167 drugs)

Browse all the conditions that are associated with Cholecystitis:

Cholecystitis (1,218 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Imbruvica) and Imbruvica (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.